LATEST NEWS AND ARTICLES
From events, scientific articles to PR, you will find here all our latest news.
- News
Poietis contributes to shaping the future standards of 3D bioprinting
On October 21, our founder Fabien Guillemot will take part in the European Commission’s Joint Research Centre workshop in Brussels:
🧬 “3D Bioprinting: Towards Standards in Biomedicine”
- Press release
Bioprinting: Poietis announces the award of a third new major European patent
Poietis, 4D Bioprinting company, announces the issuance by the European Patent Office of a third patent covering its bioprinting technology: Patent No. EP3233499 entitled «Laser printing method and device for implementing said method».
- Press release
Servier and Poietis announce scientific partnership in 4D bioprinting of liver tissues
Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues.
- Press release
Poietis launches its new 4D Bioprinting platform
Poietis, the first 4D bioprinting company, announces the commercialization of its new range of NGB systems («Next Generation Bioprinting») to cover all the tissue engineering needs, from research to clinical batches production.
- Press release
Poietis and Prometheus, division of skeletal tissue engineering of KU Leuven, enter into a Collaborative Research Agreement focused on 3D Bioprinting for skeletal ATMPs.
Poietis, leading bioprinting company and Prometheus, Division of Skeletal Tissue Engineering at KU Leuven, entered into a 2-years Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration.
- Press release
Poietis closes a 5M€ financing round to accelerate the development of its bio-printing platform for tissue therapy manufacturing
Poietis, a bioprinting leader, announces that it has closed a €5 million Series A financing round to accelerate technological developments that could lead to the first implantation of a bioprinted tissue into patients from 2021.
Do you want to know more about NGB platform?